Rapid decline in insulin antibodies and glutamic acid decarboxylase autoantibodies with ibrutinib therapy of chronic lymphocytic leukaemia.

about

Rapid decline in insulin antibodies and glutamic acid decarboxylase autoantibodies with ibrutinib therapy of chronic lymphocytic leukaemia.

Item

http://www.wikidata.org/entity/Q47820958

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Rapid decline in insulin antib ...... chronic lymphocytic leukaemia.

@en

Rapid decline in insulin antib ...... chronic lymphocytic leukaemia.

@nl

type

Item

label

Rapid decline in insulin antib ...... chronic lymphocytic leukaemia.

@en

Rapid decline in insulin antib ...... chronic lymphocytic leukaemia.

@nl

prefLabel

Rapid decline in insulin antib ...... chronic lymphocytic leukaemia.

@en

Rapid decline in insulin antib ...... chronic lymphocytic leukaemia.

@nl

P1476

Rapid decline in insulin antib ...... chronic lymphocytic leukaemia

@en

P2093

A Gessl

http://www.w3.org/2001/XMLSchema#string

C Skrabs

http://www.w3.org/2001/XMLSchema#string

U Jäger

http://www.w3.org/2001/XMLSchema#string

W F Pickl

http://www.w3.org/2001/XMLSchema#string

P2860

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Bruton's tyrosine kinase promotes persistence of mature anti-insulin B cells.

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort

Characterization of insulin antibodies by Surface Plasmon Resonance in two clinical cases: brittle diabetes and insulin autoimmune syndrome.

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.

CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy.

Ibrutinib-A double-edge sword in cancer and autoimmune disorders.

The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy.

P304

145-149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JCPT.12602

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Thomas Perkmann

P577

2017-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28753229

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

autoantibody